Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
| العنوان: | Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109) |
|---|---|
| المؤلفون: | Thomas J. Ettrich, Jens Atzpodien, Stephan Kanzler, Swen Wessendorf, Swantje Held, Petra Buechner-Steudel, Axel Florschütz, D Nörenberg, Max Seidensticker, Anke Reinacher-Schick, Jorge Riera-Knorrenschild, Dominik Paul Modest, Michael Geissler, J. Greeve, Uwe M. Martens, Volker Heinemann, Sebastian Stintzing, Andrea Tannapfel, Annika Kurreck, Thomas Seufferlein |
| المصدر: | Journal of Cancer Research and Clinical Oncology |
| بيانات النشر: | Springer Science and Business Media LLC, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, Oncology, Cancer Research, Organoplatinum Compounds, Colorectal cancer, Original Article – Clinical Oncology, Leucovorin, Disease, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, Disease dynamics, FOLFOXIRI, Metastatic colorectal cancer, Panitumumab, General Medicine, Middle Aged, Primary tumor, Treatment Outcome, 030220 oncology & carcinogenesis, Disease Progression, Female, Fluorouracil, Colorectal Neoplasms, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Randomization, BRAF, Combination chemotherapy, 03 medical and health sciences, Internal medicine, medicine, Humans, Aged, business.industry, Wild type, medicine.disease, Early tumor shrinkage, 030104 developmental biology, Tumor progression, Mutation, Primary tumor site, ras Proteins, Camptothecin, business, Depth of response |
| الوصف: | Purpose In mCRC, disease dynamics may play a critical role in the understanding of long-term outcome. We evaluated depth of response (DpR), time to DpR, and post-DpR survival as relevant endpoints. Methods We analyzed DpR by central review of computer tomography images (change from baseline to smallest tumor diameter), early tumor shrinkage (≥ 20% reduction in tumor diameter at first reassessment), time to DpR (study randomization to DpR-image), post-DpR progression-free survival (pPFS = DpR-image to tumor progression or death), and post-DpR overall survival (pOS = DpR-image to death) with special focus on BRAF status in 66 patients and primary tumor site in 86 patients treated within the VOLFI-trial, respectively. Results BRAF wild-type (BRAF-WT) compared to BRAF mutant (BRAF-MT) patients had greater DpR (− 57.6% vs. − 40.8%, p = 0.013) with a comparable time to DpR [4.0 (95% CI 3.1–4.4) vs. 3.9 (95% CI 2.5–5.5) months; p = 0.8852]. pPFS was 6.5 (95% CI 4.9–8.0) versus 2.6 (95% CI 1.2–4.0) months in favor of BRAF-WT patients (HR 0.24 (95% CI 0.11–0.53); p p Conclusions BRAF-MT patients derive a less profound treatment response compared to BRAF-WT patients. The difference in outcome according to BRAF status is evident after achievement of DpR with BRAF-MT patients hardly deriving any further disease control beyond DpR. Our observations hint towards an aggressive tumor evolution in BRAF-MT tumors, which may already be molecularly detectable at the time of DpR. |
| تدمد: | 1432-1335 0171-5216 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6834639b3ec002c9bc256673519e750Test https://doi.org/10.1007/s00432-020-03257-zTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e6834639b3ec002c9bc256673519e750 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14321335 01715216 |
|---|